Poor
Needs Label Support
Patient Risk:
Info
Summary
The AI response list contains many restart/antibody/monitoring statements that are not supported by the provided FDA label excerpts (which only cover serious infections and malignancies). The only claim that directly aligns is the generic warning theme; however, it is not specifically tied to the boxed warning wording/section in the supplied excerpts.
Category Scores
Accurate Statements
WARNING: SERIOUS INFECTIONS AND MALIGNANCY.
Supported in general by the provided HUMIRA label excerpts describing increased risk for serious infections (5.1) and malignancies (5.2), though the supplied excerpts do not explicitly provide the boxed warning section text.
Unsupported Statements
Many people who stop Humira and later restart can go back on it.
Not supported by the provided label excerpts (only serious infections and malignancies are included).
Whether restarting Humira works well can depend on why Humira was stopped and how long therapy was interrupted.
Not supported by the provided label excerpts.
The immune system may form antibodies against adalimumab during the time off therapy.
Not supported by the provided label excerpts.
Antibodies against adalimumab can make the medicine work less effectively when restarted.
Not supported by the provided label excerpts.
The longer the gap after stopping Humira, the higher the chance the body develops antibodies that reduce Humira's effect.
Not supported by the provided label excerpts.
Developing antibodies after a longer interruption can increase the likelihood of reactions when Humira is restarted.
Not supported by the provided label excerpts.
Clinicians may decide to restart Humira at the original schedule after a stop.
Not supported by the provided label excerpts.
Clinicians may decide to use a different dosing plan initially when restarting Humira.
Not supported by the provided label excerpts.
Clinicians may decide to switch therapies if Humira may be less effective after restarting.
Not supported by the provided label excerpts.
The reason Humira was stopped can affect the safest next step.
Not supported by the provided label excerpts.
If Humira was stopped because of an infection or surgery, clinicians often aim to restart once the issue is resolved.
The label excerpt says not to initiate in patients with active infection and to discontinue for serious infection/sepsis, but does not provide restart timing guidance for infections/surgery; not supported as stated.
If Humira was stopped due to side effects, the decision to restart depends on the specific reaction and whether it can be managed.
Not supported by the provided label excerpts.
If Humira was stopped because disease was controlled, restarting depends on current symptoms and inflammation status.
Not supported by the provided label excerpts.
People can respond again after restarting Humira.
Not supported by the provided label excerpts.
Not everyone gets the same level of control after restarting Humira.
Not supported by the provided label excerpts.
Loss of response is more likely if antibodies developed during the time off treatment.
Not supported by the provided label excerpts.
Loss of response is more likely after a longer interruption.
Not supported by the provided label excerpts.
Clinicians may monitor symptoms when restarting Humira after a gap.
The excerpt supports monitoring for signs/symptoms of infection during and after treatment, but does not specifically support monitoring strategy for restarting after a gap; not supported as stated.
Clinicians may consider blood testing for drug levels and antibodies when restarting after a gap.
Not supported by the provided label excerpts.
Blood testing may be particularly considered if the patient previously had reduced response or is restarting after a longer stop.
Not supported by the provided label excerpts.
Drug level/antibody testing information can help determine whether Humira is still likely to work.
Not supported by the provided label excerpts.
If Humira is held temporarily, patients should follow the prescriber's plan for when to restart.
Not supported by the provided label excerpts.
Stopping Humira abruptly without a plan can increase the chance that the condition flares.
Not supported by the provided label excerpts.
Stopping Humira abruptly without a plan can complicate restarting.
Not supported by the provided label excerpts.
Patients should not restart Humira on their own if they recently had a serious infection.
The excerpt says discontinue if a patient develops a serious infection and not to initiate in patients with an active infection, but it does not provide patient-specific restart-after-recent-serious-infection instructions; not supported as stated.
Patients should not restart Humira on their own if they have an active untreated infection.
Partially aligned with 'should not be initiated in patients with an active infection', but the excerpt is about initiation rather than restarting; not supported as stated for 'restart' and 'on their own'.
Patients should not restart Humira on their own if they have a complication from surgery.
Not supported by the provided label excerpts.
A clinician should guide the timing of restarting Humira based on the patient's situation.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
The evaluation of the 'WARNING: SERIOUS INFECTIONS AND MALIGNANCY' theme does not cite the exact boxed warning wording/section from the provided label excerpt set (only 5.1 and 5.2 text is provided).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Most restart-related claims (antibody effects, restart timing, testing, and patient instructions) are not supported by the provided label excerpts, so alignment to label-based safety guidance is weak for this specific output. The general serious infection/malignancy warning theme is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Label Support
Primary Issue
Restart/antibody/monitoring assertions are largely unsupported by the provided FDA label excerpts; only general serious infection and malignancy risk content is supported.
Suggested Improvement
Limit claims to what is contained in the provided label sections (serious infection and malignancy) or provide additional FDA label excerpts covering immunogenicity, interruption/re-initiation, monitoring for restart, and patient restart instructions; cite the exact boxed warning section wording if asserting it as a boxed warning.